Could 4 months of antiviral drugs be enough for CMV-Infected newborns?
NCT ID NCT07450365
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a 4-month course of antiviral medication (ganciclovir or valganciclovir) against the standard 6-month course for babies born with moderate-to-severe congenital CMV infection. The goal is to see if the shorter treatment works just as well at preventing long-term brain, hearing, and vision problems. About 150 newborns will be enrolled and followed until age 2.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ganciclovir or valganciclovir (antiviral drugs)
- What this could lead to
- If successful, this could show that a shorter 4-month treatment is just as effective as the standard 6-month course, reducing medication burden for babies with congenital CMV.
- What could go wrong
- This is a relatively small trial (150 babies) and is not yet recruiting. The shorter course might prove less effective at preventing long-term disabilities like hearing loss or developmental delays.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL CMV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.